LCTX vs PSA · rev $9.5M vs rev $4.82B
Lineage Cell Therapeutics Inc (LCTX) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
PSA (PSA) common stock.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
LCTX currently screens at market cap $213.6M. PSA currently screens at market cap $0.
Not investment advice. Open the LCTX and PSA stock pages for the full models.
Not investment advice.